Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 9 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.72 |
|---|---|
| 52-week range | $0.38 - $2.27 |
| 50-day moving average | $0.63 |
| 200-day moving average | $0.96 |
| Wall St. target price | $4.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.25 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.72 from 2022-07-01
| 1 week (2022-06-28) | -5.30% |
|---|---|
| 1 month (2022-06-03) | 1.41% |
| 3 months (2022-04-01) | N/A |
| 6 months (2022-01-04) | -28.00% |
| 1 year (2021-07-02) | -67.57% |
|---|---|
| 2 years (2020-07-02) | -68.28% |
| 3 years (2019-07-05) | 1.43 |
| 5 years (2017-07-05) | 5.17 |
| Revenue TTM | $5 million |
|---|---|
| Gross profit TTM | $-8,619,000 |
| Return on assets TTM | -75.34% |
| Return on equity TTM | -335.49% |
| Profit margin | 0% |
| Book value | $-1.67 |
| Market capitalisation | $55.7 million |
TTM: trailing 12 months
We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $0.382 up to $2.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -1.4043. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.
vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.